SCHEMBL575128

SCHEMBL575128

ClCCc1ccccc1Cl

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 3/20 0.62
IDO1 P14902 3/20 0.54
PNMT P11086 1/20 0.54
SLC6A2 P23975 1/20 0.52
SLC6A4 P31645 1/20 0.52
SLC6A3 Q01959 1/20 0.52
AOC3 Q16853 1/20 0.52
KCNH2 Q12809 1/20 0.52
HTR3E A5X5Y0 1/20 0.50
HTR3B O95264 1/20 0.50
HTR3A P46098 1/20 0.50
HTR3D Q70Z44 1/20 0.50
HTR3C Q8WXA8 1/20 0.50
LMNA P02545 1/20 0.45
TSHR P16473 1/20 0.45
PKM P14618 1/20 0.45
DAO P14920 2/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
CHRM2 P08172 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6740216 0.86 TAAR1 (0.71) TAAR1IDO1PNMTSLC6A2SLC6A4
SCHEMBL6684381 0.85 TAAR1 (0.58) TAAR1IDO1PNMTSLC6A2SLC6A4
SCHEMBL6679839 0.83 TAAR1 (0.56) TAAR1IDO1PNMTSLC6A2SLC6A4
SCHEMBL4574904 0.83 TAAR1 (0.40) TAAR1IDO1PNMTSLC6A2SLC6A4
SCHEMBL28700925 0.81 TAAR1 (0.54) TAAR1IDO1PNMTSLC6A2SLC6A4
SCHEMBL1822278 0.79 TAAR1 (0.62) TAAR1IDO1PNMTSLC6A2SLC6A4
SCHEMBL10911917 0.78 TAAR1 (0.60) TAAR1IDO1PNMTSLC6A2SLC6A4
SCHEMBL126469 0.78
SCHEMBL320795 0.77 TAAR1 (0.60) TAAR1IDO1PNMTSLC6A2SLC6A4
SCHEMBL5609905 0.77 TAAR1 (0.60) TAAR1IDO1PNMTSLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105523944-A Synthetic method of 2-bromo-4-(2-chloro-ethyl)-aniline UNIV CHANGZHOU 2016-04-27 CN claimed
CN-115911573-A Nonaqueous electrolyte solution for secondary battery and nonaqueous electrolyte secondary battery using same 三菱化学株式会社 2023-04-04 CN disclosed
US-11616253-B2 Nonaqueous electrolyte for secondary battery and nonaqueous-electrolyte secondary battery employing the same MITSUBISHI CHEMICAL CORPORATION (JP) 2023-03-28 US disclosed
CN-110177798-B Catalyst and process for preparing same 博里利斯股份公司 2022-08-30 CN disclosed
US-11367899-B2 Nonaqueous electrolyte for secondary battery and nonaqueous-electrolyte secondary battery employing the same MITSUBISHI CHEMICAL CORPORATION (JP) 2022-06-21 US disclosed
CN-106848406-B Nonaqueous electrolyte solution for secondary battery and nonaqueous electrolyte secondary battery 三菱化学株式会社 2020-09-11 CN disclosed
CN-111048841-A Nonaqueous electrolyte solution for secondary battery and nonaqueous electrolyte secondary battery using same 三菱化学株式会社 2020-04-21 CN disclosed
CN-105633345-B Nonaqueous electrolyte solution for secondary battery and nonaqueous electrolyte secondary battery using same 三菱化学株式会社 2020-01-17 CN disclosed
US-10468720-B2 Nonaqueous electrolyte for secondary battery and nonaqueous-electrolyte secondary battery employing the same MITSUBISHI CHEMICAL CORPORATION (JP) 2019-11-05 US disclosed
US-20190288338-A1 NONAQUEOUS ELECTROLYTE FOR SECONDARY BATTERY AND NONAQUEOUS-ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2019-09-19 US disclosed
EP-1259493-A2 SUBSTITUTED PIPERAZINE COMPOUNDS CV THERAPEUTICS, INC. (US) 2002-11-27 EP disclosed
US-6342501-B1 VIRICIDES THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2002-01-29 US disclosed
US-20010041704-A1 N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-4-phenylbutyl) -piperazinyl)acetamide, for example; useful to protect skeletal muscles against damage from trauma or disease, treat shock, preserve donor tissue or organs; greater half-life CV THERAPEUTICS, INC. 2001-11-15 US disclosed
WO-2001062744-A2 SUBSTITUTED PIPERAZINE COMPOUNDS CV THERAPEUTICS, INC. (US) 2001-08-30 WO disclosed
WO-2000042043-A1 PYRROLO[2,3-d]PYRIMIDINES AS ANTIVIRAL AGENTS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2000-07-20 WO disclosed
EP-0071833-B1 PROCESS FOR PRODUCING 4-BENZOYLPYRAZOLES ISHIHARA SANGYO KAISHA, LTD. (JP) 1987-02-04 EP disclosed
US-4560814-A Process for alkylating halogenated and trifluoromethylated benzene compounds RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1985-12-24 US disclosed
US-4415739-A Process for producing 4-benzoylpyrazoles ISHIHARA SANGYO KAISHA LTD. (JP) 1983-11-15 US disclosed
EP-0071833-A1 Process for producing 4-benzoylpyrazoles ISHIHARA SANGYO KAISHA, LTD. (JP) 1983-02-16 EP disclosed
US-4162155-A P-ACETAMIDOPHENOL AS STABILIZER FOR ISOOCTENYL 2,4-DICHLOROPHENOXY ACETATE HOWARD HALL & COMPANY (US) 1979-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010041704-A1 N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-4-phenylbutyl) -piperazinyl)acetamide, for example; useful to protect skeletal muscles against damage from trauma or disease, treat shock, preserve donor tissue or organs; greater half-life TNNC1, ATP2A1, ATP2A2 TAAR1 4462/4885IDO1 3116/4885PNMT 1845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.